# A Study of Emtricitabine/Tenofovir Disoproxil Fumarate (FTC/TDF) and MK-8527 in Healthy Participants

> **NCT06816043** · PHASE1 · COMPLETED · sponsor: **Merck Sharp & Dohme LLC** · enrollment: 20 (actual)

## Conditions studied

- Healthy

## Interventions

- **DRUG:** MK-8527
- **DRUG:** FTC/TDF

## Key facts

- **NCT ID:** NCT06816043
- **Lead sponsor:** Merck Sharp & Dohme LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2025-02-21
- **Primary completion:** 2025-06-05
- **Final completion:** 2025-06-17
- **Target enrollment:** 20 (ACTUAL)
- **Last updated:** 2025-06-27


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06816043

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06816043, "A Study of Emtricitabine/Tenofovir Disoproxil Fumarate (FTC/TDF) and MK-8527 in Healthy Participants". Retrieved via AI Analytics 2026-06-30 from https://api.ai-analytics.org/clinical/NCT06816043. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*